Cel-Sci Corporation (CVM)
| Market Cap | 744.52M |
| Revenue (ttm) | 543,473 |
| Net Income (ttm) | -32.94M |
| Shares Out | 38.67M |
| EPS (ttm) | -0.88 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 3 |
| Last Price | $18.00 |
| Previous Close | $18.75 |
| Change ($) | -0.75 |
| Change (%) | -4.00% |
| Day's Open | 19.03 |
| Day's Range | 18.02 - 19.50 |
| Day's Volume | 552,520 |
| 52-Week Range | 8.10 - 40.91 |
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation reports first quarter fiscal 2021 financial results.
Investors are betting that these three stocks could turn them into millionaires in incredibly short periods of time. Will they succeed?
CVM stock is on the move after Cel-Sci CEO Geert Kersten joined the battle against GME stock short-sellers. Here's what to know.
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation to Present at the 2021 H.C. Wainwright BIOCONNECT Virtual Conference
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation issues letter to shareholders.
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI reports fiscal 2020 financial results and clinical & corporate developments.
Data lock has been announced, and top line data is to be expected within a few weeks. Trial duration hints towards longer survival than Standard of Care.
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI announces the closing of its $14.65 million bought deal.
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Announces Bought Deal Offering.
Data is Locked. NWBO's Data Lock announcement boosted their Market Cap to nearly $2B.
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Announces Update on Phase 3 Cancer Trial Results.
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI's LEAPS Peptides Demonstrate Clear Survival Benefit as a Treatment for COVID-19 in Preclinical Studies.
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation issues letter to shareholders.
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation to Present at H.C.
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation reports third quarter fiscal 2020 financial results.
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Announces Early Results with COVID 19 LEAPS Vaccine/Treatment.
Who has the upper ground in a war between investors and short-sellers about whether a biotech's clinical trial for treating head and neck cancer can succeed?
CEL-SCI announced that it is developing an immunotherapy for COVID-19 based on its LEAPS peptide technology.
Cel-Sci: Little Known Drug Validates Multikine's Investigation Goals
The mechanism of action for cytokines in helping the immune system respond to malignant growth in the head and neck has been well documented by medical research.
Multikine's Phase 3 trial accounts for the short half-lives of cytokines post administration, which may lead to significant improvements in its clinical profile compared to Phase 2.
The world's largest head and neck cancer study should have ended in late 2018 but patients appear to be living longer.
The world's largest head and neck cancer study should have ended in late 2018, but patients appear to be living longer.
Multikine is a cytokine-based immunotherapeutic compound intended to cure Head and Neck Squamous-Cell Carcinoma, which is currently being tested in a large Phase III trial.
These stocks were huge winners last week. But can their momentum continue?
May 8, 2019 Cel-Sci Corporation released a letter to investors indicating the Phase 3 Multikine trial had not yet reached its endpoint of 298 endpoints (deaths) in the two arms.
CEL-SCI's Multikine Phase III Trial in Squamous Cell Cancer of Head and Neck Continues as the End-Point Has Still Not Yet Been Reached.
About CVM
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and ... [Read more...]
| Industry Biotechnology | IPO Date Jan 1, 1987 |
| CEO Geert Kersten | Country United States |
| Stock Exchange NYSEAMERICAN | Ticker Symbol CVM |
Financial Performance
In 2020, CVM's revenue was $597,427, an increase of 11.51% compared to the previous year's $535,776. Losses were -$30.28 million, 36.8% more than in 2019.
Analyst Forecasts
The average 12-month stock price forecast for CVM is 19.00, which is an increase of 5.56% from the latest price.